STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53 | -99.9% | 13,557 | +70.9% | 0.00% | 0.0% |
| Q3 2022 | $102,000 | -97.3% | 7,933 | -95.7% | 0.00% | -96.4% |
| Q1 2022 | $3,844,000 | +426.6% | 182,591 | +499.8% | 0.03% | +600.0% |
| Q4 2021 | $730,000 | -31.4% | 30,442 | -27.2% | 0.00% | -20.0% |
| Q3 2021 | $1,064,000 | +84.7% | 41,814 | +144.3% | 0.01% | +66.7% |
| Q2 2021 | $576,000 | +2.5% | 17,117 | +18.3% | 0.00% | 0.0% |
| Q1 2021 | $562,000 | -34.3% | 14,468 | -43.3% | 0.00% | -40.0% |
| Q3 2020 | $855,000 | +42.0% | 25,526 | +1.0% | 0.01% | 0.0% |
| Q2 2020 | $602,000 | +288.4% | 25,280 | +272.7% | 0.01% | +400.0% |
| Q1 2020 | $155,000 | +33.6% | 6,783 | +65.8% | 0.00% | 0.0% |
| Q4 2019 | $116,000 | -70.3% | 4,092 | -69.5% | 0.00% | -66.7% |
| Q2 2019 | $391,000 | – | 13,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |